Showing results (1061-1070 of 2,903) with videos related to
Sort By:
Pageof 291
Cancer Gene Therapy|July 2, 2011
Application of mRNA regulatory regions to improve tumor specificity of transgene expressionM V Shepelev, E V Korobko, G P Georgiev, et al.Cancer Gene Therapy|July 23, 2011
Gap junctions in human glioblastomas: implications for suicide gene therapyS Cottin, P V Gould, L Cantin, et al.Cancer Gene Therapy|July 16, 2011
Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32Y Qu, J L Taylor, A Bose, et al.Cancer Gene Therapy|March 27, 2007
CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunityJ Westermann, T Nguyen-Hoai, G Baldenhofer, et al.Cancer Gene Therapy|November 10, 2007
DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic miceC Curcio, A S Khan, A Amici, et al.Cancer Gene Therapy|August 21, 2007
Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructsY Folmer, M Schneider, H E Blum, et al.Cancer Gene Therapy|August 21, 2007
Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccineY-T Yo, K-F Hsu, G-S Shieh, et al.Cancer Gene Therapy|August 21, 2007
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patientsJ Nemunaitis, N Senzer, S Sarmiento, et al.Cancer Gene Therapy|November 8, 2008
An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor modelsS Dharmapuri, L Aurisicchio, P Neuner, et al.Cancer Gene Therapy|December 17, 2011
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcomaN Rainusso, V S Brawley, A Ghazi, et al.Pageof 291